- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
ATL/Interspec merger approved
The merger of ultrasound vendorsATL and Interspec was approved this week by the shareholders ofboth companies. The companies announced the merger in February(SCAN 2/16/94). Under the terms of the merger, Interspec will become a whollyowned subsidiary
The merger of ultrasound vendorsATL and Interspec was approved this week by the shareholders ofboth companies. The companies announced the merger in February(SCAN 2/16/94).
Under the terms of the merger, Interspec will become a whollyowned subsidiary of ATL through an exchange of one share of Interspecstock for 0.413 shares of ATL stock. The acquisition creates anultrasound company with combined revenues of approximately $360million and an installed base of over 20,000 systems.
Interspec chief Edward Ray will continue as president of theAmbler, PA-based company and will join ATL's board of directors.ATL is based in Bothell, WA.
Can MRI-Based AI Bolster Biopsy Decision-Making in PI-RADS 3 Cases?
December 9th 2024In patients with PI-RADS 3 lesion assessments, the combination of AI and prostate-specific antigen density (PSAD) level achieved a 78 percent sensitivity and 93 percent negative predictive value for clinically significant prostate cancer (csPCa), according to research presented at the Radiological Society of North American (RSNA) conference.
